NRC combines excellent profitability and cash-conversion metrics with having already reached its analyst price target and a negative modeled risk/reward setup, while an overbought technical condition and two large recent earnings misses add further uncertainty.
Thesis pillars
- Excellent Quality Metrics↑Improving
- Analyst Target Reached Negative Asymmetry↑Improving
- Overbought Technical Condition↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 5, 2026
NRC Health (NRC) Stock Analysis
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $23.83, but acceptable to hold if already in. Reasons: Concentration risk — Customer: healthcare industry customers; Analyst target reached - limited upside remaining.
NRC Health, formerly National Research Corporation, provides subscription-based patient experience, consumer experience, employee experience and market research analytics solutions to U.S. healthcare organizations, serving over 250 of the top 400 health systems by net patient... Read more
Hold if already holding. Not a fresh buy at $23.83, but acceptable to hold if already in. Reasons: Concentration risk — Customer: healthcare industry customers; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news boost analyst 0.60, earnings proximity 92d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About NRC Health
About NRC Health
NRC Health's ten largest customers collectively accounted for 20 percent of the company's total revenue in 2025, up from 17 percent in 2024 and 15 percent in 2023, as the roughly 45-year-old healthcare analytics provider serves more than 250 of the top 400 U.S. health systems ranked by net patient revenue. Headquartered in Lincoln, Nebraska, the company markets subscription-based Patient Experience, Consumer Experience, Employee Experience and Market Experience solutions.
NRC Health generates the majority of its revenue from renewals of subscription-based service agreements, supplemented by cross-selling additional solutions to existing customers and adding new customers, with Market Insights, its syndicated survey product, measuring roughly 300,000 healthcare consumers annually. The company competes primarily against Press Ganey and Qualtrics, both of which it believes have significantly higher annual revenue, along with healthcare organizations' internal marketing and quality-improvement departments and general market research firms. NRC Health has also grown through acquisitions, completing eight since 2001, and recently overhauled its senior leadership team, appointing Trent Green as CEO in June 2025, Shane Harrison as CFO in September 2025, and Helen Hrdy as COO in October 2024.
Show full overview
Substantially all of NRC Health's revenue is derived from customers in the healthcare industry, meaning changes in Medicare and Medicaid reimbursement policy, healthcare consolidation, or reductions in provider operating budgets flow directly into the company's results rather than being diversified away by other end markets. The 10-K also notes that health spending reached approximately $5.3 trillion, or 18 percent of U.S. GDP, in 2024, underscoring both the scale of the addressable market and NRC Health's exposure to federal and state cost-containment measures currently under consideration in Congress.
See also: Healthcare · Health Information Services
From NRC Health's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-11-02Recent Developments — NRC Health
Latest news
- NEWS NRC Health (NRC) Stock Sinks As Margin Compression Deepens Earnings Pain - simplywall.st — simplywall.st negative
- NEWS Citizens raises NRC Health stock price target on strong results - Investing.com — Investing.com positive
- NEWS NRC shares Duane Arnold restart progress at public hearing - American Nuclear Society -- ANS — American Nuclear Society -- ANS positive
- NEWS Is NRC Health (NRC) Struggling with Profitability After Q2 Earni - GuruFocus — GuruFocus negative
- NEWS Citizens raises NRC Health stock price target on strong Q3 results - Investing.com — Investing.com positive
Generated 2026-11-02T11:43:20Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomerten largest customers20%10-K Item 1A: 'Our ten largest customers collectively accounted for 20%, 17%, and 15% of our total revenue in 2025, 2024, and 2023, respectively.'
- HIGHCustomerhealthcare industry customers10-K Item 1A: 'Substantially all of our revenue is derived from customers in the healthcare industry.'
Material Events(8-K, last 90d)
- 2026-04-28Item 5.02LOWNRC Health's Compensation Committee amended prior equity awards to CEO Trent Green, COO Helen Hrdy and Chief Corporate Development Officer Andrew Monich to correct tax-timing uncertainty on vested-share treatment; a routine compensation technical fix, not a departure.SEC filing →
- 2026-04-20Item 5.02LOWNRC Health amended CFO Shane Harrison's September 2025 restricted stock award to permit voting and dividend rights on unvested shares; a routine compensatory arrangement change, not a departure.SEC filing →
- 2026-04-20Item 5.03LOWNational Research Corporation changed its corporate name to NRC Health effective April 15, 2026 via a charter amendment (no stockholder vote required, ticker unchanged), alongside a board declassification action.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $23.83, but acceptable to hold if already in. Reasons: Concentration risk — Customer: healthcare industry customers; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $22.95 reached (−3.7%), stop $22.16 (−7.5%), A.R:R -0.3:1. Score 5.9/10, moderate confidence.
Analyst target $22.95 reached (−3.7% from $23.83); no take-profit level is published. Analyst target $22.95 reached (−3.7%), stop $22.16 (−7.5%), A.R:R -0.3:1. Stop-loss: $22.16.
Concentration risk — Customer: healthcare industry customers; Analyst target reached - limited upside remaining; Near 52-week high (2.3% away).
NRC Health trades at a P/E of 88.3 (forward 22.5). TrendMatrix value score: 5.9/10. Verdict: Hold.
5 analysts cover NRC with a consensus score of 4.0/5. Average price target: $27.
What does NRC Health do?NRC Health, formerly National Research Corporation, provides subscription-based patient experience, consumer...
NRC Health, formerly National Research Corporation, provides subscription-based patient experience, consumer experience, employee experience and market research analytics solutions to U.S. healthcare organizations, serving over 250 of the top 400 health systems by net patient revenue. The company's ten largest customers accounted for 20% of total revenue in 2025, up from 17% in 2024, and substantially all of its revenue is derived from customers in the healthcare industry.